- Patient Education
Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy
Updated: Jan 27
Patient Education: Ciltacabtagene Autoleucel
Ciltacabtagene Autoleucel ( Carvykti)
FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma
On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.
Safety and efficacy were evaluated in CARTITUDE-1 (NCT03548207), an open label, multicenter clinical trial evaluating ciltacabtagene autoleucel in 97 patients with relapsed or refractory multiple myeloma who received at least three prior lines of therapy which included a PI, an IMiD, and an anti-CD38 monoclonal antibody and who had disease progression on or after the last chemotherapy regimen; 82% had received four or more prior lines of antimyeloma therapy.
Learn more:
Information on Carvykti website
INTERNATIONAL MYELOMA FOUNDATION:
CARVYKTI (ciltacabtagene autoleucel)
IMF Understanding Series
IMF Resource Library
Current FDA-Approved Medications for Multiple Myeloma Treatment
HEALTH TREE UNIVERSITY MYELOMA:
Janssen's Cilta-Cel CAR T Receives FDA Approval for Relapsed Multiple Myeloma
HealthTree University for Multiple Myeloma Lectures
Health Tree University Myeloma Videos
MULTIPLE MYELOMA RESERACH FOUNDATION:
Standard Treatments - BCMA-directed personalized immunotherapy - ciltacabtagene autoleucel or cilta-cel - Carvykti
MMRF Education Programs
MMRF Videos
References CARVYKTI- ciltacabtagene autoleucel injection, suspension:
FDA Label Prescribing Information (Revised 03/2022)
Drug Label Information at DAILYMED - NIH-National Library of Medicine
Other Resources
- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -
* Belantamab mafodotin (Withdrawn from United States market)